Quaid sues Baxter over twins' heparin overdose; Sigma taps Lazard for advice on Aspen bid;

 @FiercePharma: Moody's cuts outlook on Eli Lilly to 'negative'. Story | Follow @FiercePharma

> Dennis Quaid sued Baxter Healthcare over the life-threatening overdoses of heparin given his newborn twins three years ago; the actor has already settled with the hospital where the drug was administered. Report

> Sigma Pharmaceuticals hired Lazard Ltd. to advise it on a A$707 million ($580 million) takeover offer from Aspen Pharmacare, sources tell Bloomberg. Report

> Sun Pharmaceutical Industries reported a 26 percent drop in consolidated net profit for the year ended March 31 as regulatory issues in the U.S. hurt its performance in one of its largest markets. Report

> Abbott Laboratories on Monday sold $3 billion of senior unsecured notes, said IFR, a Thomson Reuters service. Report

> The Indian government plans to offer subsidies to medium-sized pharmaceutical firms to help them meet WHO manufacturing standards. Report

> Watson Pharmaceuticals got the FDA nod for a generic version of GlaxoSmithKline's herpes treatment Valtrex. Report

> The FDA and National Institutes of Health launched a new website that, when fully developed, will provide a mechanism for the reporting of pre- and post-market safety data to the federal government. Release

> British drugmaker GlaxoSmithKline spent just over $2.2 million lobbying the U.S. government on patent laws and other issues during the first quarter, according to a recent disclosure. Report

> Meanwhile, AstraZeneca spent $1.7 million in the first quarter lobbying in the U.S., according to its disclosure. Report

> Takeda appointed Kiyohiko Tamura as general manager of its newly established Office of the President & CEO. Report

Biotech News

 @FierceBiotech: GE brings $3B life sciences project to light. Report | Follow @FierceBiotech

 @JohnCFierce: Biosimilars, in many ways, will be even harder to test, often demanding comparative effectiveness studies with the branded biologic.| Follow @JohnCFierce

> Stem Cell Therapeutics shares blitzed after PhIIb stroke trial fails. Story

> Teva pioneering a biosimilar to compete with blockbuster Rituxan. Report

> Neurocrine shares skyrocket on promising PhII endometriosis data. News

Biotech Research News

> Who owns synthetic life forms? Report

> Singapore team offers new combo drug strategy to kill cancer cells. Story

> Australian state government touts latest research. News

> Gene therapy holds promise for muscular dystrophy patients. Article

> Stem cell team will recreate crippling brain disease in the lab. Story

Pharma Manufacturing News

> Regulators mull pros, cons of transparency efforts. Story

> Obama's advisors identify vaccine fixes. Report

> Expert tips for working with headhunters. Piece

> Intellipharmaceutics aims for abuse-deterrent painkiller. Article

> India arrests two in week of counterfeit drug raids. Report

> Students win prize for tobacco-plant vax process. Item

And Finally... A growing body of evidence links exercise and mental acuity. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.